<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myostatin (MSTN) is a muscle-specific secreted <z:chebi fb="7" ids="16670">peptide</z:chebi> that functions to limit muscle growth through an autocrine regulatory feedback loop </plain></SENT>
<SENT sid="1" pm="."><plain>Loss of MSTN activity in cattle, mice, and humans leads to a profound phenotype of muscle <z:hpo ids='HP_0001548'>overgrowth</z:hpo>, associated with more and larger fibers and enhanced regenerative capacity </plain></SENT>
<SENT sid="2" pm="."><plain>Deletion of MSTN in the mdx mouse model of Duchenne <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> enhances muscle mass and reduces disease severity </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, loss of MSTN activity in the dyW/dyW mouse model of laminin-deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, a much more severe and lethal <z:e sem="disease" ids="C0684309" disease_type="Experimental Model of Disease" abbrv="">disease model</z:e>, does not improve <z:hpo ids='HP_0000001'>all</z:hpo> aspects of muscle pathology </plain></SENT>
<SENT sid="4" pm="."><plain>Here we examined disease severity associated with myostatin (mstn-/-) deletion in mice nullizygous for delta-sarcoglycan (scgd-/-), a model of <z:hpo ids='HP_0006785'>limb-girdle muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Early loss of MSTN activity achieved either by monoclonal antibody administration or by gene deletion each improved muscle mass, regeneration, and reduced <z:mp ids='MP_0003045'>fibrosis</z:mp> in scgd-/- mice </plain></SENT>
<SENT sid="6" pm="."><plain>However, antibody-mediated inhibition of MSTN in late-stage dystrophic scgd-/- mice did not improve disease </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that MSTN inhibition may benefit <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> when instituted early or if disease is relatively mild but that MSTN inhibition in severely affected or late-stage disease may be ineffective </plain></SENT>
</text></document>